EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa

Claire Han, Karishma Patel, Haoran Gao, Jacob T Sanborn, Thomas D Nguyen iD, Jack F Klem, Brian M Ho iD, Patrick D Kenney iD, Yanan Zhao, Troy D Wood iD, Dwayne R Roach iD, Liang Chen iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00048-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Claire Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, beta-Lactams, Bacteriophages. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIA NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nosocomial Pseudomonas aeruginosa infections are among the most challenging infections to treat, and resistance to last-line agents, including polymyxins and aztreonam-based therapies, risks a future with limited or no clinical treatment options. Bacteriophages (phages) have emerged as a promising therapeutic option, both in cocktails and when given in combination with antibiotics. In this study, we show that the synergy between a lipopolysaccharide (LPS)-specific phage and antibiotics is driven by clinically relevant increases in beta-lactam permeability due to the selection of phage-resistant subpopulations. First, in the Hollow Fiber Infection Model (HFIM), we show that the combination of phage LUZ19 (pili-targeted), phage E215 (LPS-specific), and aztreonam (ATM) eradicated the laboratory host PAO1, whereas monotherapy with neither phage nor ATM could eradicate PAO1. Static time-kill studies (STKS) evaluated the LPS-specific phage PYO2 in combination with either aztreonam/avibactam (ATM/AVI) or polymyxin B (PMB) against an extensively drug-resistant clinical isolate of P. aeruginosa (AR-0231). PYO2 combined with ATM/AVI was determined to be synergistic, with a mean excess-over-bliss (EOB) of 0.350 ( P < 0.05), while PYO2 with PMB was also synergistic, with a mean EOB of 0.361 ( P < 0.05). Linear regression of STKS using sequential administration showed that, compared to antibiotic-first treatment, phage-first treatment reduced bacterial concentrations at 24 h by −6.19 log 10 colony-forming unit (CFU)/mL ( P < 0.05), with statistically significant interactions estimated for each antibiotic. These results indicated that bacterial pre-selection by PYO2 improved antibiotic activity. Mass spectrometry studies showed that the PYO2-resistant AR-0231 strain exhibited a >25% increase in the outer membrane permeability surface area coefficient for all major anti- Pseudomonal beta-lactams, including aztreonam. Altogether, our study provides mechanistic insights into phage-induced collateral sensitivity of beta-lactams. These results show how specific beta-lactams can be prioritized and optimized in phage-antibiotic combinations to maximize the antibacterial activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAnti-Bacterial Agentsbeta-LactamsBacteriophagesPseudomonas PhagesAztreonamMicrobial Sensitivity TestsLipopolysaccharidesAzabicyclo CompoundsDrug Resistance, Multiple, Bacterialbeta Lactam AntibioticsPseudomonas Infections

Stichwörter der Autor:innen

KPCLPSPseudomonas aeruginosabacteriophagebeta-lactamcarbapenemcombination therapypermeabilitypharmacodynamics

Substanzen

AztreonamAnti-Bacterial AgentsLipopolysaccharidesAzabicyclo Compoundsbeta-Lactamsbeta Lactam Antibioticsavibactam

Autor:innen und Institutionen

  • Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Department of Infectious Diseases, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Department of Chemistry, College of Arts and Sciences, University at Buffalo, Buffalo, New York, USA.
  • Department of Biology, San Diego State University, San Diego, California, USA.

ORCID-Profile: Thomas D Nguyen, Brian M Ho, Patrick D Kenney, Troy D Wood, Dwayne R Roach, Liang Chen, Nicholas M Smith

Förderung

  • NIAID NIH HHS
  • NIA NIH HHS
  • NHLBI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging

Zitieren

APA

Han, C., Patel, K., Gao, H., Sanborn, J. T., Nguyen, T. D., Klem, J. F., Ho, B. M., Kenney, P. D., Zhao, Y., Wood, T. D., Roach, D. R., Chen, L., & Smith, N. M. (2026). Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00048-26

Vancouver

Han C, Patel K, Gao H, Sanborn JT, Nguyen TD, Klem JF, et al. Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00048-26

BibTeX
@article{Han2026,
  author = {Han, Claire and Patel, Karishma and Gao, Haoran and Sanborn, Jacob T and Nguyen, Thomas D and Klem, Jack F and Ho, Brian M and Kenney, Patrick D and Zhao, Yanan and Wood, Troy D and Roach, Dwayne R and Chen, Liang and Smith, Nicholas M},
  title = {Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00048-26}
}
Kostenlos starten →